Compare CSWC & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSWC | CVAC |
|---|---|---|
| Founded | 1961 | 2000 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Textiles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | N/A | 2020 |
| Metric | CSWC | CVAC |
|---|---|---|
| Price | $22.11 | $4.49 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 3 |
| Target Price | ★ $23.50 | $6.83 |
| AVG Volume (30 Days) | 499.0K | ★ 1.2M |
| Earning Date | 02-02-2026 | 11-24-2025 |
| Dividend Yield | ★ 11.60% | N/A |
| EPS Growth | N/A | ★ 94.02 |
| EPS | ★ 1.62 | 0.94 |
| Revenue | ★ $217,271,000.00 | $83,000,117.00 |
| Revenue This Year | $13.78 | N/A |
| Revenue Next Year | $7.08 | $23.71 |
| P/E Ratio | $13.61 | ★ $4.78 |
| Revenue Growth | ★ 11.39 | N/A |
| 52 Week Low | $17.46 | $2.48 |
| 52 Week High | $23.86 | $5.72 |
| Indicator | CSWC | CVAC |
|---|---|---|
| Relative Strength Index (RSI) | 62.03 | 40.25 |
| Support Level | $21.33 | $4.26 |
| Resistance Level | $22.52 | $4.36 |
| Average True Range (ATR) | 0.27 | 0.17 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 64.03 | 40.16 |
Capital Southwest Corp is a U.S.-based investment company that specializes in providing customized financing to middle market companies across various industries. The company's investment objective is to produce attractive risk-adjusted returns by generating current income from debt investments and capital appreciation from equity and equity related investments. It focuses on providing flexible financing solutions through partnerships with business owners, management teams, and financial sponsors. The company's portfolio may include senior debt, second lien, and subordinated debt, preferred stocks, common stocks, and warrants. The primary source company's revenue comprises interest income and dividend income from investments made as well as management fees.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.